Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults
Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of...
Gespeichert in:
Veröffentlicht in: | Journal of allergy and clinical immunology 2015-09, Vol.136 (3), p.601-609 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 609 |
---|---|
container_issue | 3 |
container_start_page | 601 |
container_title | Journal of allergy and clinical immunology |
container_volume | 136 |
creator | Fingleton, James, PhD Travers, Justin, MBChB Williams, Mathew, Dip Ex Sci Charles, Thomas, DipSM Bowles, Darren, MBChB Strik, Rianne, BSc Shirtcliffe, Philippa, MBChB Weatherall, Mark, MBChB Beasley, Richard, DSc |
description | Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy. |
doi_str_mv | 10.1016/j.jaci.2015.01.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717495407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674915001037</els_id><sourcerecordid>3796333671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</originalsourceid><addsrcrecordid>eNqNkl-L1TAQxYMo7nX1C_ggBV986TWTNGkDIiyL_2DBh12fQ5pOMbVtapKu9NubeleFfRBhIEz4zYEzZwh5DvQIFOTr4TgY646MgjhSyMUfkANQVZeyYeIhOVCqoJR1pc7IkxgHmnveqMfkjIm6kkrKA7m-CWjShHMqAsbFz9Hd4owxFr4vlq84-7Qt-KuL27QkP5nkbGFc-GG2_N3GFFabnJ8LNxemW8cUn5JHvRkjPrt7z8mX9-9uLj-WV58_fLq8uCqtaGQqLfLKGFAGoOGNaWxju5byihvVyU6B4VyJ3tKWtq2pGUcQXV1bYJbJqreSn5NXJ90l-O8rxqQnFy2Oo5nRr1FDDdm7qGj9PyiVggm2q768hw5-DXM2kimqWAVSskyxE2WDjzFgr5fgJhM2DVTv6ehB7-noPR1NIRfPQy_upNd2wu7PyO84MvDmBGBe263DoKN1OFvsXECbdOfdv_Xf3hu3o5udNeM33DD-9aEj01Rf7_exnwcISoHymv8EmYK1nw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709241662</pqid></control><display><type>article</type><title>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fingleton, James, PhD ; Travers, Justin, MBChB ; Williams, Mathew, Dip Ex Sci ; Charles, Thomas, DipSM ; Bowles, Darren, MBChB ; Strik, Rianne, BSc ; Shirtcliffe, Philippa, MBChB ; Weatherall, Mark, MBChB ; Beasley, Richard, DSc</creator><creatorcontrib>Fingleton, James, PhD ; Travers, Justin, MBChB ; Williams, Mathew, Dip Ex Sci ; Charles, Thomas, DipSM ; Bowles, Darren, MBChB ; Strik, Rianne, BSc ; Shirtcliffe, Philippa, MBChB ; Weatherall, Mark, MBChB ; Beasley, Richard, DSc ; New Zealand Respiratory Health Survey Study Group</creatorcontrib><description>Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2015.01.013</identifier><identifier>PMID: 25746966</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adrenergic beta-2 Receptor Agonists - therapeutic use ; Adult ; Aged ; Airway Obstruction - complications ; Airway Obstruction - drug therapy ; Airway Obstruction - pathology ; Albuterol - therapeutic use ; Allergy and Immunology ; Anti-Asthmatic Agents - therapeutic use ; Asthma ; Asthma - complications ; Asthma - drug therapy ; Asthma - pathology ; Biomarkers ; bronchodilator ; Budesonide - therapeutic use ; Chronic obstructive pulmonary disease ; Cluster Analysis ; Disease control ; Female ; Gastroesophageal reflux ; Genotype & phenotype ; Glucocorticoids - therapeutic use ; Humans ; inhaled corticosteroid ; Ipratropium - therapeutic use ; Male ; Middle Aged ; Muscarinic Antagonists - therapeutic use ; Nitric oxide ; Obesity - complications ; Obesity - drug therapy ; Obesity - pathology ; Phenotype ; Pulmonary Disease, Chronic Obstructive - complications ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - pathology ; Questionnaires ; Risk factors ; Severity of Illness Index ; Surveys and Questionnaires ; Treatment Outcome</subject><ispartof>Journal of allergy and clinical immunology, 2015-09, Vol.136 (3), p.601-609</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2015 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</citedby><cites>FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</cites><orcidid>0000-0003-0337-406X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2015.01.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25746966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fingleton, James, PhD</creatorcontrib><creatorcontrib>Travers, Justin, MBChB</creatorcontrib><creatorcontrib>Williams, Mathew, Dip Ex Sci</creatorcontrib><creatorcontrib>Charles, Thomas, DipSM</creatorcontrib><creatorcontrib>Bowles, Darren, MBChB</creatorcontrib><creatorcontrib>Strik, Rianne, BSc</creatorcontrib><creatorcontrib>Shirtcliffe, Philippa, MBChB</creatorcontrib><creatorcontrib>Weatherall, Mark, MBChB</creatorcontrib><creatorcontrib>Beasley, Richard, DSc</creatorcontrib><creatorcontrib>New Zealand Respiratory Health Survey Study Group</creatorcontrib><title>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.</description><subject>Adolescent</subject><subject>Adrenergic beta-2 Receptor Agonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Airway Obstruction - complications</subject><subject>Airway Obstruction - drug therapy</subject><subject>Airway Obstruction - pathology</subject><subject>Albuterol - therapeutic use</subject><subject>Allergy and Immunology</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - complications</subject><subject>Asthma - drug therapy</subject><subject>Asthma - pathology</subject><subject>Biomarkers</subject><subject>bronchodilator</subject><subject>Budesonide - therapeutic use</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cluster Analysis</subject><subject>Disease control</subject><subject>Female</subject><subject>Gastroesophageal reflux</subject><subject>Genotype & phenotype</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>inhaled corticosteroid</subject><subject>Ipratropium - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscarinic Antagonists - therapeutic use</subject><subject>Nitric oxide</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - pathology</subject><subject>Phenotype</subject><subject>Pulmonary Disease, Chronic Obstructive - complications</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - pathology</subject><subject>Questionnaires</subject><subject>Risk factors</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl-L1TAQxYMo7nX1C_ggBV986TWTNGkDIiyL_2DBh12fQ5pOMbVtapKu9NubeleFfRBhIEz4zYEzZwh5DvQIFOTr4TgY646MgjhSyMUfkANQVZeyYeIhOVCqoJR1pc7IkxgHmnveqMfkjIm6kkrKA7m-CWjShHMqAsbFz9Hd4owxFr4vlq84-7Qt-KuL27QkP5nkbGFc-GG2_N3GFFabnJ8LNxemW8cUn5JHvRkjPrt7z8mX9-9uLj-WV58_fLq8uCqtaGQqLfLKGFAGoOGNaWxju5byihvVyU6B4VyJ3tKWtq2pGUcQXV1bYJbJqreSn5NXJ90l-O8rxqQnFy2Oo5nRr1FDDdm7qGj9PyiVggm2q768hw5-DXM2kimqWAVSskyxE2WDjzFgr5fgJhM2DVTv6ehB7-noPR1NIRfPQy_upNd2wu7PyO84MvDmBGBe263DoKN1OFvsXECbdOfdv_Xf3hu3o5udNeM33DD-9aEj01Rf7_exnwcISoHymv8EmYK1nw</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Fingleton, James, PhD</creator><creator>Travers, Justin, MBChB</creator><creator>Williams, Mathew, Dip Ex Sci</creator><creator>Charles, Thomas, DipSM</creator><creator>Bowles, Darren, MBChB</creator><creator>Strik, Rianne, BSc</creator><creator>Shirtcliffe, Philippa, MBChB</creator><creator>Weatherall, Mark, MBChB</creator><creator>Beasley, Richard, DSc</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0337-406X</orcidid></search><sort><creationdate>20150901</creationdate><title>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</title><author>Fingleton, James, PhD ; Travers, Justin, MBChB ; Williams, Mathew, Dip Ex Sci ; Charles, Thomas, DipSM ; Bowles, Darren, MBChB ; Strik, Rianne, BSc ; Shirtcliffe, Philippa, MBChB ; Weatherall, Mark, MBChB ; Beasley, Richard, DSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-ce34aa19a11838a8c8cdb0343a9d6d91a3395fc0b0bba723e15d77c12c264fc63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adrenergic beta-2 Receptor Agonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Airway Obstruction - complications</topic><topic>Airway Obstruction - drug therapy</topic><topic>Airway Obstruction - pathology</topic><topic>Albuterol - therapeutic use</topic><topic>Allergy and Immunology</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - complications</topic><topic>Asthma - drug therapy</topic><topic>Asthma - pathology</topic><topic>Biomarkers</topic><topic>bronchodilator</topic><topic>Budesonide - therapeutic use</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cluster Analysis</topic><topic>Disease control</topic><topic>Female</topic><topic>Gastroesophageal reflux</topic><topic>Genotype & phenotype</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>inhaled corticosteroid</topic><topic>Ipratropium - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscarinic Antagonists - therapeutic use</topic><topic>Nitric oxide</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - pathology</topic><topic>Phenotype</topic><topic>Pulmonary Disease, Chronic Obstructive - complications</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - pathology</topic><topic>Questionnaires</topic><topic>Risk factors</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fingleton, James, PhD</creatorcontrib><creatorcontrib>Travers, Justin, MBChB</creatorcontrib><creatorcontrib>Williams, Mathew, Dip Ex Sci</creatorcontrib><creatorcontrib>Charles, Thomas, DipSM</creatorcontrib><creatorcontrib>Bowles, Darren, MBChB</creatorcontrib><creatorcontrib>Strik, Rianne, BSc</creatorcontrib><creatorcontrib>Shirtcliffe, Philippa, MBChB</creatorcontrib><creatorcontrib>Weatherall, Mark, MBChB</creatorcontrib><creatorcontrib>Beasley, Richard, DSc</creatorcontrib><creatorcontrib>New Zealand Respiratory Health Survey Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fingleton, James, PhD</au><au>Travers, Justin, MBChB</au><au>Williams, Mathew, Dip Ex Sci</au><au>Charles, Thomas, DipSM</au><au>Bowles, Darren, MBChB</au><au>Strik, Rianne, BSc</au><au>Shirtcliffe, Philippa, MBChB</au><au>Weatherall, Mark, MBChB</au><au>Beasley, Richard, DSc</au><aucorp>New Zealand Respiratory Health Survey Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>136</volume><issue>3</issue><spage>601</spage><epage>609</epage><pages>601-609</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Background Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. Methods We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25746966</pmid><doi>10.1016/j.jaci.2015.01.013</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0337-406X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-6749 |
ispartof | Journal of allergy and clinical immunology, 2015-09, Vol.136 (3), p.601-609 |
issn | 0091-6749 1097-6825 |
language | eng |
recordid | cdi_proquest_miscellaneous_1717495407 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adolescent Adrenergic beta-2 Receptor Agonists - therapeutic use Adult Aged Airway Obstruction - complications Airway Obstruction - drug therapy Airway Obstruction - pathology Albuterol - therapeutic use Allergy and Immunology Anti-Asthmatic Agents - therapeutic use Asthma Asthma - complications Asthma - drug therapy Asthma - pathology Biomarkers bronchodilator Budesonide - therapeutic use Chronic obstructive pulmonary disease Cluster Analysis Disease control Female Gastroesophageal reflux Genotype & phenotype Glucocorticoids - therapeutic use Humans inhaled corticosteroid Ipratropium - therapeutic use Male Middle Aged Muscarinic Antagonists - therapeutic use Nitric oxide Obesity - complications Obesity - drug therapy Obesity - pathology Phenotype Pulmonary Disease, Chronic Obstructive - complications Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - pathology Questionnaires Risk factors Severity of Illness Index Surveys and Questionnaires Treatment Outcome |
title | Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T01%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20responsiveness%20of%20phenotypes%20of%20symptomatic%20airways%20obstruction%20in%20adults&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Fingleton,%20James,%20PhD&rft.aucorp=New%20Zealand%20Respiratory%20Health%20Survey%20Study%20Group&rft.date=2015-09-01&rft.volume=136&rft.issue=3&rft.spage=601&rft.epage=609&rft.pages=601-609&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2015.01.013&rft_dat=%3Cproquest_cross%3E3796333671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1709241662&rft_id=info:pmid/25746966&rft_els_id=1_s2_0_S0091674915001037&rfr_iscdi=true |